Hassenbusch, MD, PhD PRS Leadership & Institutional Service Award, The University of Texas MD Anderson Cancer Center, 2022 - Present Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2020 - Present Vice-Chair, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2019 - Present Member, CME Advisory Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2019 Member- Division of Cancer Medicine, PRS Clinical Revenue Cycle Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2015 - 2017 Member, Institutional Review Board 5, The University of Texas MD Anderson Cancer Center, 2013 - Present Member, Institutional Research Grant Study Section Review Committee for Clinical Translational and Population-based Research Projects, The University of Texas MD Anderson Cancer Center, 2012 - Present Member, Clinical Research Committee 1, The University of Texas MD Anderson Cancer Center, 2012 - 2014 Associate Member, Institutional Review Board 5, The University of Texas MD Anderson Cancer Center, 2012 - 2013 Committee Chair, Institutional Research Grant Study Section Review Committee for Clinical Translational and Population-based Research Projects, The University of Texas MD Anderson Cancer Center, 2011 - 2012 Member, Institutional Review Board 5, The University of Texas MD Anderson Cancer Center, 2011 - 2012 Vice Chairman, Institutional Research Grant Study Section Review Committee for Clinical Translational and Population-based Research Projects, The University of Texas MD Anderson Cancer Center, 2010 - 2011 Member, Institutional Research Grant Study Section Review Committee for Clinical Translational and Population-based Research Projects, The University of Texas MD Anderson Cancer Center, 2009 - 2010 Member, Clinical Research Committee 4, The University of Texas MD Anderson Cancer Center, 2007 - 2010 Member, Sepsis Order Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2007 Member, Anemia Guidelines Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2007 Editorial Activities Editorial Board Member, Leukemia & Lymphoma, 2021 - Present Editorial Board Member, American Journal of Hematology, 2019 - 2022 Editorial Board Member, Acta Haematologica, 2017 Associate Editor, Frontiers in Hematology Oncology, 2011 Editorial Board Member, Personalized Medicine in Oncology, 2011 Honors & Awards Professional Memberships Society of Hematologic Oncology 2013 - Present Indo-American Cancer Association 2011 - Present Harris County Medical Society 2007 - Present Texas Medical Society 2007 - Present American Association for Cancer Research 2006 - Present American Society of Hematology 2001 - Present American Society of Clinical Oncology 2001 - Present Selected Presentations & Talks Local Presentations 2025
A good rule of thumb is to take it first thing in the morning or at least 30 to 60 minutes before you eat anything
10.1007/s00405-021-06628-5 39 LeeH
Researchers even believe GHK controls thousands of genes related to regeneration and inflammation, which is why GHK has been studied so much in regards to longevity medicine
